---
title: "12 Health Care Stocks Moving In Friday's After-Market Session"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295979468.md"
description: "During Friday's after-market session, several healthcare stocks experienced significant volatility. Gainers included iTonic Holdings (up 32%), Quanterix (up 8.88%), and Obsidian Therapeutics (up 6.92%). Conversely, losers featured Streamex (down 11.5%), Ensysce Biosciences (down 11.28%), and Cue Biopharma (down 9.27%). Many price movements coincided with recent Q2 earnings reports."
datetime: "2026-08-14T21:06:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295979468.md)
  - [en](https://longbridge.com/en/news/295979468.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295979468.md)
---

# 12 Health Care Stocks Moving In Friday's After-Market Session

### Gainers

-   **iTonic Holdings** (NASDAQ:ITOC) stock moved upwards by 32.0% to $0.41 during Friday's after-market session. The company's market cap stands at $4.9 million.
-   **Quanterix** (NASDAQ:QTRX) shares increased by 8.88% to $2.82. The company's market cap stands at $135.2 million. As per the news, the Q2 earnings report came out 4 days ago.
-   **Obsidian Therapeutics** (NASDAQ:OBX) shares increased by 6.92% to $19.0. The market value of their outstanding shares is at $1.1 billion.
-   **AEON Biopharma** (AMEX:AEON) shares moved upwards by 5.34% to $0.29. The company's market cap stands at $11.9 million. As per the news, the Q2 earnings report came out 2 days ago.
-   **TransCode Therapeutics** (NASDAQ:RNAZ) shares increased by 5.18% to $3.45. The market value of their outstanding shares is at $3.6 million.
-   **Milestone Scientific** (AMEX:MLSS) shares rose 4.86% to $0.52. The company's market cap stands at $48.7 million. As per the news, the Q2 earnings report came out yesterday.

### Losers

-   **Streamex** (NASDAQ:STEX) shares decreased by 11.5% to $0.92 during Friday's after-market session. The market value of their outstanding shares is at $90.2 million. As per the news, the Q2 earnings report came out today.
-   **Ensysce Biosciences** (NASDAQ:ENSC) stock fell 11.28% to $0.35. The market value of their outstanding shares is at $5.3 million. As per the press release, Q2 earnings came out yesterday.
-   **Cue Biopharma** (NASDAQ:CUE) stock decreased by 9.27% to $31.03. The company's market cap stands at $130.5 million. As per the press release, Q2 earnings came out today.
-   **Cerenome** (NASDAQ:CNSY) shares fell 8.55% to $3.37. The market value of their outstanding shares is at $25.4 million.
-   **ENvue Medical** (NASDAQ:FEED) shares fell 8.47% to $0.4. The company's market cap stands at $3.5 million.
-   **60 Degrees** (NASDAQ:SXTP) shares declined by 6.97% to $1.11. The market value of their outstanding shares is at $3.3 million. As per the press release, Q2 earnings came out today. **See Also:** www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

### Related Stocks

- [OBX.US](https://longbridge.com/en/quote/OBX.US.md)
- [QTRX.US](https://longbridge.com/en/quote/QTRX.US.md)
- [CUE.US](https://longbridge.com/en/quote/CUE.US.md)
- [ITOC.US](https://longbridge.com/en/quote/ITOC.US.md)
- [ENSC.US](https://longbridge.com/en/quote/ENSC.US.md)
- [AEON.US](https://longbridge.com/en/quote/AEON.US.md)
- [RNAZ.US](https://longbridge.com/en/quote/RNAZ.US.md)
- [MLSS.US](https://longbridge.com/en/quote/MLSS.US.md)
- [STEX.US](https://longbridge.com/en/quote/STEX.US.md)
- [CNSY.US](https://longbridge.com/en/quote/CNSY.US.md)
- [FEED.US](https://longbridge.com/en/quote/FEED.US.md)
- [SXTP.US](https://longbridge.com/en/quote/SXTP.US.md)
- [ENSCW.US](https://longbridge.com/en/quote/ENSCW.US.md)
- [SXTPW.US](https://longbridge.com/en/quote/SXTPW.US.md)

## Related News & Research

- [Cue Biopharma Chief Executive Officer Sold Shares Worth Over $1.6M](https://longbridge.com/en/news/295986047.md)
- [Ensysce Biosciences director Bob G. Gower acquires common shares worth $443,025.17](https://longbridge.com/en/news/296210667.md)
- [Quanterix Reshapes Sales Strategy, Targets Q4 FDA Decision for Alzheimer’s Blood Test](https://longbridge.com/en/news/296029225.md)
- [Ensysce Biosciences Q2 net loss widens on higher R&D costs](https://longbridge.com/en/news/295841617.md)
- [Visa, Lockheed Martin And A Health Care Stock On CNBC’s ‘Final Trades’](https://longbridge.com/en/news/296127265.md)